25 RECREATION PARK DR SUITE 108, HINGHAM, MA
Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
To Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology
Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
News
Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Changes in Board, Management or Compensation
Q2
Q1
FY 2024
Q3
FY 2023
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement